WSA maintains guidance despite strong growth – CEO explains why

A stringent focus on prices and costs has helped WS Audiology book a revenue growth of 20% despite global supply issues and increasing inflation, CEO Eric Bernard tells MedWatch.

Eric Bernard, CEO of WS Audiology | Photo: WS Audiology / PR

WS Audiology is well on the way to solidifying the financial year of 2021/2022 as a great one for the hearing aid manufacturer.

With two quarters over and done with, WSA has reported figures for the first half of its financial year, booking a revenue of EUR 1,163m, which corresponds to 17% growth and organic growth of 12%.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs